用于阿尔茨海默病诊断和预后的多模态技术。
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.
作者信息
Perrin Richard J, Fagan Anne M, Holtzman David M
机构信息
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.
出版信息
Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538.
Abstract
Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.
摘要
阿尔茨海默病影响着全球数百万人。目前，尚无预防或减缓该疾病的治疗方法。与其他神经退行性疾病一样，阿尔茨海默病的特征是大脑中的蛋白质错误折叠。这个过程以及相关的脑损伤在痴呆症所伴随的实质性神经退行性变出现的数年前就已开始。使用新的神经成像技术和液体生物标志物的研究表明，阿尔茨海默病的病理变化在临床前就可以被检测到。这些进展应该能够设计新的临床试验和基于早期机制的治疗干预措施。
相似文献
1
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.用于阿尔茨海默病诊断和预后的多模态技术。
Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538.
2
Cerebrospinal fluid biomarkers of Alzheimer's disease.阿尔茨海默病的脑脊液生物标志物。
Biomark Med. 2010 Feb;4(1):51-63. doi: 10.2217/BMM.09.83.
3
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.PTI-125 降低阿尔茨海默病患者的生物标志物。
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
4
Current understanding of Alzheimer's disease diagnosis and treatment.阿尔茨海默病诊断与治疗的当前认识
F1000Res. 2018 Jul 31;7. doi: 10.12688/f1000research.14506.1. eCollection 2018.
5
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.阿尔茨海默病中的 Tau 生物标志物：迈向临床实践和试验的应用。
Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25.
6
Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics.阿尔茨海默病的血液生物标志物：推进非侵入性诊断和预后评估。
Int J Mol Sci. 2024 Oct 10;25(20):10911. doi: 10.3390/ijms252010911.
7
New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease.阿尔茨海默病中新型液体生物标志物追踪非淀粉样β和非tau 病理学。
Exp Mol Med. 2020 Apr;52(4):556-568. doi: 10.1038/s12276-020-0418-9. Epub 2020 Apr 13.
8
Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.阿尔茨海默病的核心生物标志物候选物——诊断、预后预测及生物活性反映的前景
J Neural Transm (Vienna). 2004 Mar;111(3):247-72. doi: 10.1007/s00702-003-0065-z. Epub 2003 Dec 3.
9
Marking the markers of Alzheimer's: too good to diagnose, too bad to use?标记阿尔茨海默病的标志物：诊断效果太好而无法使用，使用效果太差而无法诊断？
Neuropsychopharmacol Hung. 2012 Sep;14(3):165-76.
10
Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages.脑脊液蛋白质组学鉴定淀粉样蛋白和tau蛋白PET分期的生物标志物
Cell Rep Med. 2025 Apr 15;6(4):102031. doi: 10.1016/j.xcrm.2025.102031. Epub 2025 Mar 20.
引用本文的文献
1
Multilayer Integration of Networks Toolbox (MINT).网络多层集成工具箱（MINT）。
Commun Biol. 2025 Jun 7;8(1):894. doi: 10.1038/s42003-025-08269-4.
2
Intranasal Delivery of Metabolically Resilient Glutathione: Pharmacokinetic, Permeation, and Efficacy Studies.代谢适应性谷胱甘肽的鼻腔给药：药代动力学、渗透及疗效研究
Mol Pharm. 2025 Jul 7;22(7):4145-4157. doi: 10.1021/acs.molpharmaceut.5c00382. Epub 2025 May 22.
3
Identifying suppressive factors of Alzheimer's disease through comprehensive analysis of real-world data: a single-center retrospective study.通过对真实世界数据的综合分析确定阿尔茨海默病的抑制因素：一项单中心回顾性研究
BMC Geriatr. 2025 May 9;25(1):321. doi: 10.1186/s12877-025-05982-x.
4
Exploring the Aβ Plaque Microenvironment in Alzheimer's Disease Model Mice by Multimodal Lipid-Protein-Histology Imaging on a Benchtop Mass Spectrometer.利用台式质谱仪上的多模态脂质-蛋白质-组织学成像技术探索阿尔茨海默病模型小鼠的Aβ斑块微环境
Pharmaceuticals (Basel). 2025 Feb 13;18(2):252. doi: 10.3390/ph18020252.
5
Altered immune response is associated with sex difference in vulnerability to Alzheimer's disease in human prefrontal cortex.免疫反应改变与人类前额叶皮质对阿尔茨海默病易感性的性别差异有关。
Brain Pathol. 2025 May;35(3):e13318. doi: 10.1111/bpa.13318. Epub 2024 Nov 4.
6
2-Phenylbenzothiazolyl iridium complexes as inhibitors and probes of amyloid β aggregation.2-苯基苯并噻唑基铱配合物作为淀粉样β聚集的抑制剂和探针。
Dalton Trans. 2024 Aug 27;53(34):14258-14264. doi: 10.1039/d4dt01691b.
7
Multi-Threshold Recurrence Rate Plot: A Novel Methodology for EEG Analysis in Alzheimer's Disease and Frontotemporal Dementia.多阈值递归率图：一种用于阿尔茨海默病和额颞叶痴呆脑电图分析的新方法。
Brain Sci. 2024 Jun 1;14(6):565. doi: 10.3390/brainsci14060565.
8
Alzheimer's disease pathophysiology in the Retina.视网膜中的阿尔茨海默病病理生理学。
Prog Retin Eye Res. 2024 Jul;101:101273. doi: 10.1016/j.preteyeres.2024.101273. Epub 2024 May 15.
9
Correlation analysis of peripheral platelet markers and disease phenotypes in Alzheimer's disease.阿尔茨海默病外周血小板标志物与疾病表型的相关性分析。
Alzheimers Dement. 2024 Jun;20(6):4366-4372. doi: 10.1002/alz.13841. Epub 2024 May 7.
10
Spatiotemporal development of the neuronal accumulation of amyloid precursor protein and the amyloid plaque formation in the brain of 3xTg-AD mice.3xTg-AD小鼠大脑中淀粉样前体蛋白的神经元积累及淀粉样斑块形成的时空发展
Heliyon. 2024 Mar 30;10(7):e28821. doi: 10.1016/j.heliyon.2024.e28821. eCollection 2024 Apr 15.
本文引用的文献
1
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.鉴定和验证阿尔茨海默病早期阶段的新型脑脊液生物标志物。
Proteomics Clin Appl. 2007 Nov;1(11):1373-84. doi: 10.1002/prca.200600999. Epub 2007 Oct 16.
2
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.非痴呆性衰老的神经病理学：临床前阿尔茨海默病的推测性证据。
Neurobiol Aging. 2009 Jul;30(7):1026-36. doi: 10.1016/j.neurobiolaging.2009.04.002. Epub 2009 Apr 18.
3
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.γ-分泌酶抑制剂可降低中枢神经系统中β-淀粉样蛋白的生成。
Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.
4
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.脑脊液β淀粉样蛋白42和tau蛋白作为大脑中阿尔茨海默病型病理变化的生物标志物。
Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.
5
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.脑脊液β淀粉样蛋白42（Abeta[42]）水平降低与认知正常老年人的脑萎缩相关。
Ann Neurol. 2009 Feb;65(2):176-83. doi: 10.1002/ana.21559.
6
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.基于蛋白质组学鉴定早期阿尔茨海默病中与海马体代谢相关的血浆蛋白。
J Neurol. 2008 Nov;255(11):1712-20. doi: 10.1007/s00415-008-0006-8. Epub 2008 Aug 1.
7
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.用正电子发射断层扫描（PET）和[11C]-L-司来吉兰-D2评估脑中单胺氧化酶B（MAO-B）占有率：一项针对新型MAO-B抑制剂EVT 301的剂量探索研究。
Clin Pharmacol Ther. 2009 May;85(5):506-12. doi: 10.1038/clpt.2008.241. Epub 2009 Jan 7.
8
Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.阿尔茨海默病风险变异体与脑脊液β淀粉样蛋白存在关联。
Neurogenetics. 2009 Feb;10(1):13-7. doi: 10.1007/s10048-008-0150-4. Epub 2008 Sep 24.
9
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.阿尔茨海默病中的小胶质细胞、淀粉样蛋白与认知：一项[11C]（R）PK11195-PET和[11C]PIB-PET研究。
Neurobiol Dis. 2008 Dec;32(3):412-9. doi: 10.1016/j.nbd.2008.08.001. Epub 2008 Aug 15.
10
Amyloid-beta dynamics correlate with neurological status in the injured human brain.β-淀粉样蛋白动力学与人类受伤大脑的神经状态相关。
Science. 2008 Aug 29;321(5893):1221-4. doi: 10.1126/science.1161591.
Zotero 插件